Description
LS-11 is an investigational medication being studied in clinical trials. It is a photosensitive drug used in a specific type of treatment called photodynamic therapy (PDT). PDT involves injecting a drug that becomes activated by light. In the trials, LS-11 is administered intravenously (injected into a vein). After about an hour, a special catheter is inserted directly into the tumor through a minor surgical procedure, guided by CT scans. Light energy is then delivered through the catheter into the tumor for a period of time. The catheter is then removed. This light activation is intended to kill cancer cells. The treatment is being studied in patients whose solid tumors have not responded to standard treatments. Patients are monitored closely after treatment with scans and tests to check for safety, drug clearance, tumor cell death, and treatment response. Patients are also asked to avoid exposure to external light for a period after receiving the drug.
Mechanism of Action
LS-11 is a photosensitizing agent. This means it is a drug that becomes toxic to cells when exposed to light of a specific wavelength. In this treatment approach (photodynamic therapy), the drug is administered systemically (likely intravenously, based on the trial description). It accumulates in the tumor tissue. A light delivery device is then inserted directly into the tumor. When light is applied, the LS-11 becomes activated, generating reactive oxygen species that damage and kill the cancer cells in the targeted area.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.